Home
Centre for International Health

PROMISE M & S

Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety

The Centre for International Health has been engaged in the follow up study of the large prevention of mother to child transmission trial PROMISE PEP: Prevention of mother to child transmission of HIV.

Important aims of the follow up were:

  • To assess the long-term safety and efficacy of one-year infant prophylaxis using lamivudine (3TC) or lopinavir/ritonavir (LPV/r) to prevent post-natal transmission through breastfeeding.
  • To compare the long-term safety of infant prophylaxis using either 3TC versus LPV/r on child development (growth, somatic and mental health), mortality, adrenal function, liver function, full blood count and mitochondrial toxicity.

The study was structured in two parts. The 'clinical & biological safety' component involved a cross sectional survey. A clinical and neuropsychological examination of participants were conducted. In addition biological samples were collected.

In 2018, the research group had their final PROMISE M and S consortium meeting and the current work involves data analysis and dissemination.